D R. PROCTOR HARVEY, Dr. Braunwald, Ladies and Gentlemen, I am deeply conscious of the honor you have bestowed upon me as a surgeon in asking me to give this lecture. Although modesty is not a quality with which surgeons are generally overendowed, I would like to accept it as a tribute to my colleagues both medical and surgical who work with me at Guy's and National Heart Hospitals in London. In fact, teamwork is the feature which has characterized modern cardiac surgery and distinguishes it from that of our predecessors. I am sure I speak for my surgical colleagues on both sides of the Atlantic when I say that ours is a unique and I am sure coveted relationship, where cardiologists and cardiac surgeons work together in a truly interdependent manner fulfilling an ideal which in other branches of our profession is often a meaningless and hollow gesture of clinical cooperation.
When I undertook to give this lecture, I did so feeling I was on familiar ground but I did not appreciate the considerable task I would encounter in trying to make a brief assessment of biologic valves today. For instance, far from assessing world trends, I quickly found that my own thoughts were in need of clarification. Hoping to draw inspiration from my colleagues by comparing results I found this also fraught with problems.
For instance it has become a bad habit, which we all share, that when talking about heart-valve prostheses we tend to give the results and extoll the virtues of model A and then later, when problems arise with it, present instead only the trouble-free results from model B ( fig. 1 ). This sequence then continues for a number of years so that by a combination of increasing experience and improved technical developments one is finally able to present the recent and excellent trouble-free results with model C or D. At the same time, if pressed, one can acknowledge like a man the shortcomings of the earlier model A, "which of course is no longer used."
Yet, if one looks closely at the various prosthetic valves there has been little fundamental design change, just like the new automobile which appears annually with a different metallic skin covering the same familiar mechanics.
Again, with say homograft aortic valves, nothing fundamental has changed in the design principle since it was introduced several million years ago, but there has been a little bit of juggling with the preparation and storage media in which they are immersed. This again introduces the temptation to give only recent good results with the latest storage preparation.
Since the aortic homograft among biologic valves has had the longest run, one can try to assess how in our hands it matches the results with mechanical prostheses reported from other centers over a similar period of time. Also one can look at some alternative biologic valves which we have used and see whether Figure 1 The popularity of a particular. valve 5 ). For instance, we had expected to be able to show that the homograft survival prospects were better than those for the mechanical valves. In fact it appears that in this experience there is little to choose between the two types of valve substitute over this period of time but that whatever form of valve replacement is used the result is a good deal better than the outlook for the natural history of aortic stenosis showin on the same graph.
However, there are currently a number of ways of presenting survivors and survivor statistics. For instance the previously mentioned series of 282 cases operated upon by me and for which hard data are available can be shown in a very favorable light by presenting and following only the 235 survivors. This is achieved by moving the scale to the right by 1 month, which effectively excludes the operative mortality and gives the curve a substantial lift up. Survivor curve for homograft series from Guy's Hospital and the National Heart Hospital compared with a mean survivor curve for five prosthetic valve series. The survivor curve for untreated aortic stenosis is also included.
;~~~~PATIENT SURVIVAL CURVE Personal series presented as a survivor curve. Of the causes of failure, avulsion and rupture of the valves usually occurred during the first 18 months of surgery whereas calcification in the freeze-dried valves has been an increasing phenomenon after 3 years ( fig. 9 ). Bacterial endocarditis oin the other hand has occurred at any time after valve replacement with an overall incidence of 3.9%.
There has been a dramatic reduction in the number of valve failures, and 42 of the 46 valve failures observed in this long-term study occurred in the first 4 years ( fig. 10) 
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Steps in the pulnmonary autograft "cswitch" operation. in all areas until we can analyze our failures more fully and digest the results.
Having briefly discussed performance in a selection of biologic valves, brings me to the more difficult subject of prospects for biologic valves. To my mind, this adds up to the problem of developing a satisfactory mitral valve substitute.
It seems to me that almost any valve substitute currently available can be expected to give good results in the aortic areas but they all have disadvantages wheni transfered to the mitral area. This is certainly true in my hands for preserved aortic valve homografts when used in an iniverted position as a mitral valve substitute ( fig. 17 ), for although they have certain advantages inherenlt in all biologic valves, particularly in relation to thromboembolism, they do not match up to their lonigterm performance in the aortic area. Although freeze-dried, their earlier degeneration anid higher incidence of perforationi must surely be of signiificance, although I concede that results with fresh valves are encouraging.14 As has been already pointed out, the three cusp fascia lata valves have also performed well in the aortic area but are less satisfactory when inverted in the mitral ring, and I believe this to be true also for all types of mechanical prostheses. Since the materials used, whether homograft, fascia, or plastic and metal, are the same in all instances, whether used as an aortic or mitral replacement, the difference in their behavior in the two areas must lie in their unsuitable design or the environmental factors operating in this area. AORTIC MITRAL Figure 18 The basic design for the aortic and mitral prosthesis is identical. The valve is simply inverted. Further evidence for the need to change our mitral valve pattern to a more naturally occurring bicuspid one has come from the operative and autopsy observations on living fascial valves inserted in the mitral region. These have failed in a uniform manner in that the anterior leaflet corresponding to the large anterior mitral cusp has been preserved in all ROSS cases while the two posteriorly placed leaflets have retracted or have even fused to reproduce fairly closely the niormal mitral configuration. This phenomenon (bicuspidization) seems to have been brought about by the moulding effects of the blood flow on this plastic living tissue and cannot easily be igniored ( fig. 20) . It may be that the biologic valve's greatest challenge and its brightest prospect lie in the possibility that it may enable us to reproduce as nearly as possible the niaturally occurring mitral valve as a large flexible bicuspid mechanism.
Our earliest attempts to achieve this were with cadaveric mitral homograft valves which on a theoretic basis should work best.
Although these iniitially functioned efficiently they failed as late as 10-11 months (postoperatively) through shearing of their thin avascular nonliving chordae tendinae. Nevertheless, I
suspect that with fresh, living, mitral homografts the possibility of success with this valve is not ruled out, although the papillary muscle fixationi is ofteni difficult.
More recently we have completed a large series of dissections and exploratory studies aimed at providing a cylindrical bicuspid valve of faseia lata which can be attached to the papillary muscles or to a flexible strut which does not interfere with the mobility of the valve ring. 20 We have inserted a series of 15 of these valves, and 11 are alive over 1 year anid are beinig assessed at present.
If we are to profit fully from our studies of the naturally occurring valves, then we have to accept all of niature's criteria, anid this applies not only to design but equally to the materials we choose ( fig. 21 ). In this respect, The tricuspid valve remains a more distant challenge and for most of us is an area to avoid valve replacement if possible. Where it is unavoidable and also in cases of Ebstein's disease I currently use an inverted aortic homograft fixed on a frame, and I believe this to be the best available tricuspid valve substitute. This therefore means that biologic valves have now been adapted to all four valve areas but they have so far gained acceptance chiefly in the aortic and pulmonary sites.
In conclusion, I have tried as far as possible to retain a measure of objectivity in discussing these valves, although this is not an attitude that comes easily when discussing a subject of major interest. It seems at present that the honors are fairly evenly divided between mechanical and biologic valves as far as operative mortality and early performance are concerned. However, I feel satisfied that the continued performance and prospects are ultimately better for the aortic patient with a biologic valve free from the hazards of embolism and sudden mechanical failure.
The more distant prospects are speculative, but I would hope that mitral valve patients should be able to share this outlook without the tyranny of pills, doctors, and electrocardiograms and with a chance to live and function as normal members of the community, even to hope and plan a future, or in Hamlet's immortal words:
. . . "tis a consummation Devoutly to be wish'd. To die, to sleep:
To sleep: perchance to dream: ay, there's the rub."
